FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine

Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms, but can be serious for infants and older adults, resulting in an average of 60,000-160,000 hospitalizations and around 600-10,000 deaths per year in the US, with the highest death in people over 65. There is great news that on May 3, 2023, FDA approved the world’s first RSV vaccine for use in people aged 60 and older.

Results from…